论文部分内容阅读
目的 :探讨维拉帕米对室上性心动过速患者电生理影响。方法 :选择2014年6月~2015年12月在我院接受救治的122例室上性心动过速患,患者均给予维拉帕米静脉推注5-10mg,记录用药后患者是否转复,以及用药前后电生理参数、血压改变情况。结果 :对室上性心动过速AVNRT患者静脉注射维拉帕米后,ERPFP、ERPSP、P-R、SNRT与用药前比较,差异均具有统计学意义,CSNRT与用药前比较,差异无统计学意义。对室上性心动过速AVRT患者静脉注射维拉帕米后,ERPFP、P-R、SNRT、CSNRT与用药前比较,差异均具有统计学意义。对室上性心动过速患者静脉注射维拉帕米后,收缩压用药前(20.61±2.93)k Pa用药后降至(15.82±1.73)k Pa;舒张压用药前(14.79±2.53)k Pa用药后降至(11.97±1.75)k Pa,比较差异均具有统计学意义。经维拉帕米治疗后,AVNRT有效率为93.18%;AVRT有效率为88.46%,总有效率为90.16%(110/122)。结论 :维拉帕米能对室上性心动过速患者的ERPFP、ERPSP、P-R、SNRT、CSNRT(AVNRT组除外)均有明显的延长作用,可在短时间内终止室上性心动过速,且PSVT终止对绝大多数患者有较好的效果。虽然使患者的血压出现不同程度上的下降,但影响不大。
Objective: To investigate the electrophysiological effects of verapamil on patients with supraventricular tachycardia. Methods: A total of 122 patients with supraventricular tachycardia who were treated in our hospital from June 2014 to December 2015 were enrolled in this study. The patients were given intravenous injection of verapamil 5-10mg, and the patients were recorded after treatment. And before and after treatment electrophysiological parameters, blood pressure changes. Results: The differences of ERPFP, ERPSP, P-R and SNRT between before and after intravenous injection of verapamil in patients with supraventricular tachycardia were statistically significant. There was no significant difference between CSNRT and before treatment. After intravenous injection of verapamil in patients with supraventricular tachycardia (AVRT), the differences of ERPFP, P-R, SNRT and CSNRT before treatment were statistically significant. Before intravenous injection of verapamil in patients with supraventricular tachycardia, systolic blood pressure (20.61 ± 2.93) kPa was decreased to (15.82 ± 1.73) kPa before medication and (14.79 ± 2.53) kPa before medication After treatment to (11.97 ± 1.75) kPa, the difference was statistically significant. After verapamil treatment, AVNRT effective rate was 93.18%; AVRT effective rate was 88.46%, the total effective rate was 90.16% (110/122). Conclusion: Verapamil can significantly prolong the ERPFP, ERPSP, PR, SNRT and CSNRT (except AVNRT group) in patients with supraventricular tachycardia, and can terminate supraventricular tachycardia in a short time, And PSVT termination of the vast majority of patients have a good effect. Although the patient’s blood pressure appears to varying degrees of decline, but little effect.